The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer

Nenhuma Miniatura disponível
Citações na Scopus
33
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
PASSIGLIA, Francesco
GIOVANNETTI, Elisa
GIALLOMBARDO, Marco
LISTI, Angela
DIANA, Patrizia
CIRRINCIONE, Girolamo
CAGLEVIC, Christian
RAEZ, Luis E.
RUSSO, Antonio
Citação
EXPERT OPINION ON INVESTIGATIONAL DRUGS, v.25, n.4, p.385-392, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Molecular alterations in neurotrophic tyrosine kinase (NTRK) genes have been identified in several solid tumors including lung cancer. Pre-clinical and clinical evidence suggested their potential role as oncogenic drivers and predictive biomarkers for targeted inhibition, leading to the clinical development of a new class of compounds blocking the NTRK molecular pathway, which are currently undner early clinical investigation. Area covered: This review describes the biology of the NTRK pathway and its molecular alterations in lung cancer. It focuses on the pre-clinical and clinical development of emerging NTRK inhibitors, which have shown very promising activity in early phase I studies. Expert opinion: Among the several NTRK-inhibitors, entrectinib and LOXO-101 are those in more advanced stage of clinical development. Both agents have shown encouraging activity along with a tolerable safety profile in patients with different solid tumors harboring NTRK-fusions, emerging as new promising therapeutic options for molecularly selected patients with advanced Trk-driven lung cancers. Results from ongoing phase II basket trials are eagerly awaited.
Palavras-chave
NTRK-inhibitors, NTRK1/2/3, targeted therapy, lung cancer, TrkA/B/C
URI
https://observatorio.fm.usp.br/handle/OPI/14444
Referências
  1. Anderson D, 2014, EUR J CANCER, V50, P101
  2. LOEB DM, 1994, J BIOL CHEM, V269, P8901
  3. Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741
  4. Sholl LM, 2015, J THORAC ONCOL, V10, P768, DOI 10.1097/JTO.0000000000000516
  5. Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352
  6. Okamura K, 2012, LUNG CANCER, V78, P100, DOI 10.1016/j.lungcan.2012.07.011
  7. Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.3.CO;2-U
  8. Bishop JA, 2013, HUM PATHOL, V44, P1982, DOI 10.1016/j.humpath.2013.03.017
  9. Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938
  10. Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815
  11. Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3
  12. Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484
  13. Odate S, 2013, LUNG CANCER, V79, P205, DOI 10.1016/j.lungcan.2012.12.004
  14. Doebele RC, 2015, CANCER DISCOV, V5, P1049, DOI 10.1158/2159-8290.CD-15-0443
  15. KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y
  16. Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184
  17. [Anonymous], 2016, CANC DISCOV, V6, pOF4
  18. Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682
  19. Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000
  20. Longo FM, 2013, NAT REV DRUG DISCOV, V12, P507, DOI 10.1038/nrd4024
  21. Ardini E, 2014, MOL ONCOL, V8, P1495, DOI 10.1016/j.molonc.2014.06.001
  22. Passiglia F, 2015, EXPERT OPIN BIOL TH, V15, P1553, DOI 10.1517/14712598.2015.1071348
  23. KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0
  24. SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0
  25. Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0
  26. Sinkevicius KW, 2014, P NATL ACAD SCI USA, V111, P10299, DOI 10.1073/pnas.1404399111
  27. Farago AF, 2015, J THORAC ONCOL, V10, P1670, DOI 10.1097/01.JTO.0000473485.38553.f0
  28. Harada T, 2011, CLIN CANCER RES, V17, P2638, DOI 10.1158/1078-0432.CCR-10-3034
  29. Greco A, 2010, MOL CELL ENDOCRINOL, V321, P44, DOI 10.1016/j.mce.2009.10.009
  30. Odate S, 2013, ANTICANCER RES, V33, P3699
  31. Siniscalco D, 2011, CURR NEUROPHARMACOL, V9, P523, DOI 10.2174/157015911798376208
  32. Bronte G, 2014, CRIT REV ONCOL HEMAT, V89, P300, DOI 10.1016/j.critrevonc.2013.08.003
  33. Pierotti MA, 1998, RECENT RES CANCER, V154, P237
  34. Ardini E., 2009, MOL CANCER THER, V8, pA243
  35. Ardini E, 2013, ALK INHIBITOR NMS E6
  36. Burris HA, 2015, J CLIN ONCOL S, V33
  37. Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
  38. De Braud FG, 2015, J CLIN ONCOL, V33
  39. Kim DW, 2012, J CLIN ONCOL S, V30, P2012
  40. Nanda N, 2015, J CLIN ONCOL S, V33
  41. Patel MR, 2015, J CLIN ONCOL, V33
  42. Raez LE, 2015, J THORAC ONCOL, V10
  43. Rolfo Christian, 2014, Transl Lung Cancer Res, V3, P250, DOI 10.3978/j.issn.2218-6751.2014.03.01
  44. Ross JS, 2014, ONCOLOGIST, V19, P235, DOI 10.1634/theoncologist.2013-0352
  45. Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846
  46. Tatematsu T, 2014, MOL CLIN ONCOL, V2, P725
  47. Varella-Garcia M, 2015, J THORAC ONCOL, V10
  48. Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116
  49. Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03